Gene therapy with rAAV2, using a RPE-specific promoter, has been shown to produce efficient and exclusive gene expression in RPE cells, and has been evaluated for use in a gene therapy trial for retinitis pigmentosa due to mutations in MERTK (NM_006343), an RPE-expressed gene13. The gene discussed is MERTK; the disease is retinitis pigmentosa.